Comparative Pharmacology
Head-to-head clinical analysis: CLINDA DERM versus ELASE CHLOROMYCETIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLINDA DERM versus ELASE CHLOROMYCETIN.
CLINDA-DERM vs ELASE-CHLOROMYCETIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Clindamycin binds to the 50S ribosomal subunit of bacteria, inhibiting protein synthesis by interfering with peptide chain formation. It has bacteriostatic activity against susceptible organisms.
Elase-Chloromycetin is a combination product containing fibrinolysin and desoxyribonuclease (Elase) for enzymatic debridement, and chloramphenicol (Chloromycetin), a bacteriostatic antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit.
Topical: Apply a thin film to affected area twice daily. For acne vulgaris, available as 1% gel, lotion, or solution.
Topical application: Apply thin layer to affected area 2-3 times daily.
None Documented
None Documented
2-4 hours (terminal half-life) in adults with normal renal function; prolonged in hepatic impairment (up to 8-12 hours) and severe renal impairment.
Chloramphenicol has a terminal elimination half-life of 1.5 to 4.0 hours in adults with normal renal and hepatic function. In neonates, half-life can be prolonged to 24-48 hours, necessitating dose adjustment. Elase has no systemic half-life as it acts locally.
Primarily renal (10-20% unchanged; remainder as metabolites) and biliary/fecal (approximately 40-50% of dose as metabolites in feces).
Chloramphenicol is primarily excreted renally (approximately 90% as inactive metabolites). Fecal excretion accounts for less than 1% of the dose. Biliary elimination is negligible. Elase (fibrinolysin and desoxyribonuclease) is locally degraded and not systemically absorbed, thus its excretion is irrelevant.
Category C
Category C
Topical Antibiotic
Topical Antibiotic and Debriding Agent